Research programme: CNS disorder therapeutics - Rodin Therapeutics

Drug Profile

Research programme: CNS disorder therapeutics - Rodin Therapeutics

Latest Information Update: 17 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Rodin Therapeutics
  • Class Small molecules
  • Mechanism of Action HDAC2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Alzheimer's disease; CNS disorders

Most Recent Events

  • 17 Nov 2017 Rodin Therapeutics plans clinical development for Parkinson’s disease
  • 06 Jan 2016 Rodin Therapeutics and Biogen enter into a research and development collaboration for the development of therapeutics for the treatment of central nervous system diseases
  • 06 Oct 2015 Early research in Alzheimer's disease in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top